Latest news with #GD
Elle
3 days ago
- Entertainment
- Elle
等待6年天后Jolin蔡依林回歸！專輯同名單曲〈Pleasure〉上線，蔡依林：現在我想誠實面對自己
華語流行天后蔡依林睽違6年的全新專輯《Pleasure》宣告6月回歸；5月23日同名單曲〈Pleasure〉的封面視覺照「愉悅沉癮」搶先曝光，沿襲首波視覺「美杜莎慾望桂冠」挑戰視覺極限，此次Jolin戲劇張力十足地演譯罪與慾的濃烈交織，指上刺青「Pleasure」揭露慾望的存在，象徵慾望之繩的髮辮卻被緊緊抓牢，視覺照展現出渴望掙脫罪惡感面對慾望的強烈情境。 Jolin全新專輯《Pleasure》同名單曲率先揭開愉悅序幕，化身愉悅之母高唱「Call me Mommy」，以充滿母性的溫柔姿態和眾人一起誠實面對自我，釋放慾望、直視真實，心境遊走在罪惡感與愉悅快感的邊緣。 之所以命名「Pleasure」為專輯名稱及核心，一切源於Jolin的一次自我凝視：「我好像從來沒有停下來問過自己，我喜歡什麼？」 社會總用既定眼光審視「需求」，將深層慾望視而不潔，把表層快感貶為膚淺，讓「愉悅」成了被刻意迴避的主題，我們從不正面談論，也從未真正觸及。現階段的JOLIN選擇誠實面對自己。 她說：「我很想要活出不一樣的女性模樣。」Jolin嘗試用作品鬆綁集體潛意識的枷鎖，將『性』與『人性』放入專輯中，想透過自己的生活經驗與歌迷交流，「我覺得已經能夠面對自己比較醜陋的那一面了。」 此次Jolin大膽演譯罪與慾的濃烈交織，赤裸揭示人性深層的慾望，只見畫面中Jolin指上的「Pleasure」標示了人性最底層對愉悅的渴望，同時象徵慾望之繩的辮髮卻被緊緊抓牢，展現了慾望的壓抑與釋放、愉悅與罪惡同時的並存。 透過如此真實的一面，從未停止探索自己的Jolin意識到這段旅程永無止盡；藉由作品，Jolin也不斷發掘自己不同於過往的面貌，令她在過程中感到驚喜與滿足。她並非定義「慾望」，而純粹想分享：「這些經驗，我也有過。」不需因為面對慾望而感到害羞或罪惡。 蔡依林新歌〈Pleasure〉歌詞 Call me MommyTell me, my little bunnyHoney, tease mePlease meYou know you want meThat's my pleasureShe's not a serpent企圖讓你失了魂是罪惡溫存 為了我的想要極速快樂 要了 犯了 別等犯 犯了 別忍懂你等你直搗我的快樂It's my pleasureYou and me, babyYou and you and me, babyYou and you and meIt's my pleasureYou and me, babyYou and you and me, babyYou and you and meYou and me, you and meCall me MommyTell me, my little bunnyHoney, tease mePlease meYou know you want me黑暗中如影蛇行七情六慾五味雜陳不四不三兩面一體罪惡快感It's my pleasureYou and me, babyYou and you and me, babyYou and you and meIt's my pleasureYou and me, babyYou and you and me, babyYou and you and meYou and me我就是你 臍帶相連陰晴圓缺 欲望有罪愉悅主義 能量不滅百無禁忌 樂園萬歲Nice to meet you it's my pleasureYou know I can give you pleasureTeach you how to do it betterTake you to another level(Ha) Nice to meet you it's my pleasure(Ha) You know I can give you pleasure(Ha) Teach you how to do it better(Ha) Take you to another levelThat's my pleasureThat's my pleasureThat's my pleasureThat's my pleasure 【延伸閱讀】 >>蔡依林Jolin的15個人生金句！「謝謝曾經不看好我的人，讓我一直很努力」激勵在逆境中成長的我們 >>2025韓星來台演唱會＆見面會總整理！韓國天團2NE1、GD、BABYMONSTER演唱會時間購票一次看>>【ELLE封面人物】四十沒有不惑，反而更充滿疑惑，蔡依林：「生命充滿無常，即使是白雪公主，也需要知道人生並沒有那麼完美。」 >> 絕美精靈女王駕到！蔡依林：當你的心是滿的，你就會知道你不需要再去跟別人比較
Yahoo
3 days ago
- Business
- Yahoo
General Dynamics (GD) Outpaces Stock Market Gains: What You Should Know
The latest trading session saw General Dynamics (GD) ending at $275.20, denoting a +0.57% adjustment from its last day's close. The stock's change was more than the S&P 500's daily gain of 0.4%. Elsewhere, the Dow saw an upswing of 0.28%, while the tech-heavy Nasdaq appreciated by 0.39%. Heading into today, shares of the defense contractor had gained 0.56% over the past month, lagging the Aerospace sector's gain of 10.75% and the S&P 500's gain of 6.69% in that time. The upcoming earnings release of General Dynamics will be of great interest to investors. The company is predicted to post an EPS of $3.46, indicating a 6.13% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $12.05 billion, up 0.59% from the prior-year quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.91 per share and revenue of $50.47 billion. These totals would mark changes of +9.39% and +5.76%, respectively, from last year. Investors might also notice recent changes to analyst estimates for General Dynamics. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.03% increase. Currently, General Dynamics is carrying a Zacks Rank of #3 (Hold). In the context of valuation, General Dynamics is at present trading with a Forward P/E ratio of 18.35. This indicates a discount in contrast to its industry's Forward P/E of 22.42. It's also important to note that GD currently trades at a PEG ratio of 1.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Aerospace - Defense stocks are, on average, holding a PEG ratio of 1.92 based on yesterday's closing prices. The Aerospace - Defense industry is part of the Aerospace sector. This industry, currently bearing a Zacks Industry Rank of 40, finds itself in the top 17% echelons of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report General Dynamics Corporation (GD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and a potentially registrational study in Sjögren's disease (SjD), both expected to start in summer 2025 Positive data from first-generation batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) demonstrated that deeper IgG reductions correlated with improved clinical outcomes across a range of assessments and timepoints suggesting a potential best-in-class efficacy profile for IMVT-1402 Current cash balance provides runway for announced indications through GD readout expected in 2027 NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2025. Recent Highlights and Upcoming Milestones: In April 2025, Immunovant announced changes to its leadership team as part of a broader strategic transition with Roivant increasing operational involvement and oversight of Immunovant. Eric Venker, M.D. was appointed as CEO of Immunovant, and Tiago Girao as CFO of Immunovant. Given the strength of its potential best-in-class profile, IMVT-1402 is being developed in six announced indications, including potentially registrational trials in Graves' disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD), and a proof-of-concept trial in cutaneous lupus erythematosus (CLE). In March 2025, Immunovant announced positive results from its batoclimab MG and CIDP studies. The potentially registrational study in MG met its primary endpoint of change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in the AChR+ population at week 12, with the higher dose arm achieving a 5.6-point improvement (with 74% mean IgG reduction) and the lower dose arm achieving a 4.7-point improvement (with 64% mean IgG reduction). Initial results from week 12 of the Phase 2b CIDP study demonstrated a mean improvement in the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%. In both batoclimab studies, deeper IgG reductions correlated with improved clinical outcomes across a range of assessments and timepoints. Potentially registrational trials for IMVT-1402 in both MG and CIDP are actively enrolling. In March 2025, Immunovant initiated a potentially registrational trial of IMVT-1402 in adult participants with active, anti-citrullinated protein autoantibody (ACPA) positive D2T RA and a proof-of-concept study in CLE. Both indications represent potential first-in-class and best-in-class opportunities based on positive in-class competitor data (D2T RA) and promising efficacy data from patients dosed with IMVT-1402 as part of an open-label case study program (CLE). Immunovant plans to initiate a potentially registrational trial evaluating IMVT-1402 in SjD and a second potentially registrational trial in GD in the summer of 2025. Immunovant expects to report batoclimab six-month remission data from the proof-of-concept study in GD in the summer of 2025 and Phase 3 thyroid eye disease (TED) data in the second half of calendar year 2025. Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2025: Cash Position: As of March 31, 2025, Immunovant's cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027. R&D Expenses: Research and development expenses were $93.7 million for the three months ended March 31, 2025, compared to $66.1 million for the three months ended March 31, 2024. The increase was primarily due to activities related to our clinical trials of IMVT-1402, including contract manufacturing costs and elevated personnel-related expenses. The increase was partially offset by lower overall costs related to our IMVT-1402 Phase 1 trial and nonclinical studies. G&A Expenses: General and administrative expenses were $20.2 million for the three months ended March 31, 2025, compared to $14.8 million for the three months ended March 31, 2024. The increase was primarily due to higher personnel-related expenses, information technology costs, legal and other professional fees, and market research costs. Net Loss: Net loss was $106.4 million ($0.64 per common share) for the three months ended March 31, 2025, compared to $75.3 million ($0.52 per common share) for the three months ended March 31, 2024. Net loss for the three months ended March 31, 2025 and March 31, 2024 included $11.7 million and $9.7 million, respectively, related to non-cash stock-based compensation expense. Common Stock: As of March 31, 2025, there were 170,111,593 shares of common stock issued and outstanding. Financial Highlights for Fiscal Year Ended March 31, 2025: R&D Expenses: Research and development expenses were $360.9 million for the fiscal year ended March 31, 2025, compared to $212.9 million for the fiscal year ended March 31, 2024. The increase was primarily due to activities related to our clinical trials of IMVT-1402, including contract manufacturing costs, elevated personnel-related expenses, and higher overall clinical trial costs related to our batoclimab pivotal clinical trials. The increase was partially offset by lower overall costs related to our IMVT-1402 Phase 1 trial and nonclinical studies. IPR&D Expenses: There were no acquired in-process research and development expenses for the fiscal year ended March 31, 2025. During the fiscal year ended March 31, 2024, acquired in-process research and development expenses were $12.5 million related to the achievement of development and regulatory milestones for batoclimab under the terms of the HanAll in-license agreement. G&A Expenses: General and administrative expenses were $77.2 million for the fiscal year ended March 31, 2025, compared to $57.3 million for the fiscal year ended March 31, 2024. The increase was primarily due to higher personnel-related expenses, professional fees, information technology costs, and market research costs. Net Loss: Net loss was $413.8 million ($2.73 per common share) for the fiscal year ended March 31, 2025, compared to $259.3 million ($1.88 per common share) for the fiscal year ended March 31, 2024. Net loss for the fiscal year ended March 31, 2025 and 2024 included $49.5 million and $41.1 million, respectively, related to non-cash stock-based compensation expense. About Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," 'may,' 'might,' 'will,' 'would,' 'should,' 'expect,' 'believe,' 'estimate,' 'design,' 'plan,' "intend," and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include statements regarding Immunovant's expectations regarding the timing, design, and results of clinical trials of IMVT-1402; Immunovant's plan to develop IMVT-1402 and batoclimab across a broad range of indications; the number and timing of potentially registrational programs and clinical trials Immunovant plans to initiate for IMVT-1402; and potential benefits of IMVT-1402's unique product attributes and potential best-in-class and first-in-class profile. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant's product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant's scientific approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant's product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of global factors, such as international trade tariffs, geopolitical tensions, and adverse macroeconomic conditions on Immunovant's business operations and supply chain, including its clinical development plans and timelines; Immunovant's business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402 or batoclimab; Immunovant is at various stages of clinical development for IMVT-1402 and batoclimab; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant's periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled 'Risk Factors' in Immunovant's Annual Report on Form 10-K filed with the SEC on May 29, 2025, and Immunovant's subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or INC. Consolidated Statements of Operations (In thousands, except share and per share data) Three Months EndedMarch 31, Years EndedMarch 31, 2025 2024 2025 2024 Operating expenses: Research and development $ 93,652 $ 66,056 $ 360,917 $ 212,928 Acquired in-process research and development — — — 12,500 General and administrative 20,174 14,823 77,235 57,281 Total operating expenses 113,826 80,879 438,152 282,709 Interest income (6,889 ) (8,379 ) (24,732 ) (24,948 ) Other (income) expense, net (1,071 ) 2,587 (471 ) 1,008 Loss before provision for income taxes (105,866 ) (75,087 ) (412,949 ) (258,769 ) Provision for income taxes 583 232 891 567 Net loss $ (106,449 ) $ (75,319 ) $ (413,840 ) $ (259,336 ) Net loss per common share – basic and diluted $ (0.64 ) $ (0.52 ) $ (2.73 ) $ (1.88 ) Weighted-average common shares outstanding – basic and diluted 166,732,686 145,355,546 151,573,553 138,100,577 IMMUNOVANT, Balance Sheets(In thousands, except share and per share data) March 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 713,971 $ 635,365 Accounts receivable 2,084 5,337 Prepaid expenses and other current assets 51,180 24,902 Income tax receivable 427 166 Total current assets 767,662 665,770 Operating lease right-of-use assets 98 133 Property and equipment, net 844 462 Other assets 7,618 — Total assets $ 776,222 $ 666,365 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 17,656 $ 7,155 Accrued expenses 50,748 41,300 Current portion of operating lease liabilities 98 138 Due to Roivant Sciences Ltd. 273 15 Total current liabilities 68,775 48,608 Total liabilities 68,775 48,608 Commitments and contingencies Stockholders' equity: Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at March 31, 2025 and March 31, 2024 — — Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2025 and March 31, 2024 — — Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025 and 500,000,000 shares authorized, 145,582,999 shares issued and outstanding at March 31, 2024 16 14 Additional paid-in capital 1,945,495 1,441,518 Accumulated other comprehensive income 1,459 1,908 Accumulated deficit (1,239,523 ) (825,683 ) Total stockholders' equity 707,447 617,757 Total liabilities and stockholders' equity $ 776,222 $ 666,365 Contacts:Investors Keyur Media Stephanie in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News18
4 days ago
- General
- News18
SSC GD Constable Result 2025: GD Results Soon At ssc.gov.in, Check Marking Scheme
Last Updated: The SSC GD Constable Result 2025 will be released soon on Candidates who qualify the CBT held from February 4 to 25 will proceed to the PET stage. SSC GD Constable Result 2025: The Staff Selection Commission (SSC) will soon release the SSC GD Constable Result 2025 on its official website at After the results, candidates will also be able to check the SSC GD cut-off marks. The SSC GD Constable exam was held in a computer-based format at various centres across India from February 4 to 25, 2025. The answer key for the exam was released on March 4, 2025. Candidates who qualify in this written test (CBT 1) will move on to the next stage — the Physical Efficiency Test (PET). The selection process for SSC GD 2025 includes three stages: Event Date SSC GD Exam Date 2025 February 4 – 25, 2025 SSC GD Answer Key Release Date March 4, 2025 SSC GD Answer Key Challenge Window March 4 to 9, 2025 SSC GD Result 2025 Date To be announced How To Check SSC GD Constable Result 2025? Follow these simple steps to check your SSC GD result: Step 1: Go to the official SSC website – Step 5: Use Ctrl + F to search for your roll number in the list. SSC GD stands for Staff Selection Commission General Duty. It refers to the SSC GD Constable exam, a national-level recruitment exam conducted by the Staff Selection Commission (SSC) to recruit candidates for the General Duty Constable posts in various paramilitary forces and police organisations of the central government. These forces include: First Published: May 29, 2025, 09:08 IST
Medscape
5 days ago
- General
- Medscape
NICU Admissions Higher in Pregestational Diabetes
Neonatal intensive care unit (NICU) admission rates were significantly higher among infants born to mothers with pregestational diabetes than among those born to mothers with gestational diabetes (GD). METHODOLOGY: This Irish study compared risks for NICU admission across maternal diabetes subtypes (type 1 diabetes [T1D], type 2 diabetes [T2D], and GD) to refine counselling and neonatal care. Researchers conducted a retrospective analysis of 25,238 births (January 2018 to December 2020) and identified 3905 neonates born ≥ 34 weeks to mothers with diabetes, including those with T1D (n = 67), T2D (n = 60), and GD (n = 3712). Data on gestational age, birth weight, mode of delivery, and maternal age were extracted from the registry. NICU admission details (indications, hypoglycaemia, and respiratory support) and maternal characteristics (body mass index [BMI] > 30 and preeclampsia) were obtained via electronic records. The analysis was performed using quasi-Poisson regression for assessing NICU admission risk ratios (RRs), analysis of variance for comparing gestational age/birth weight, and chi-square tests for comparing categorical variables. The primary outcome was the NICU admission rate; secondary outcomes included respiratory distress, severe hypoglycaemia, and maternal discharge timing. TAKEAWAY: Neonates born to mothers with T1D and T2D had a admission rate of 41.8% (RR, 3.32) and 31.1% (RR, 3.89), respectively, with both significantly higher than that in those born to mothers with GD (12.5%; RR, 0.133; P ≤ .001); the hospital baseline admission rate was 11.5%. ≤ .001); the hospital baseline admission rate was 11.5%. Neonates of mothers with T1D were born earlier (mean, 37 + 1 weeks) than those of mothers with T2D (mean, 38 + 1 weeks; P = .0019) and GD (mean, 39 weeks; P ≤ .001). = .0019) and GD (mean, 39 weeks; ≤ .001). Moreover, they showed significantly higher birth weight centiles than those of mothers with T2D and GD at 25th (T1D vs T2D, P = .0042; T1D vs GD, P ≤ .001), median ( P ≤ .0001 for both), and 75th centiles (T1D vs T2D, P ≤ .0001; T1D vs GD, P = .0009). = .0042; T1D vs GD, ≤ .001), median ( ≤ .0001 for both), and 75th centiles (T1D vs T2D, ≤ .0001; T1D vs GD, = .0009). Respiratory distress dominated T1D admissions (36.7%), while hypoglycaemia was primary in T2D (73.7%). Mothers with pregestational diabetes were more frequently discharged before their infants (T1D, 42.9%; T2D, 31.5%) than those with GD (21.2%). IN PRACTICE: "It is important to counsel mothers on risks and expectations for the newborn period," the authors of the study wrote. "The aim of our study is to describe how the type of maternal diabetes impacts admission to NICU and to provide up-to-date, local data to support healthcare professionals when counselling patients with diabetes in pregnancy," they added. SOURCE: This study was led by Dearbhla Hillick, Rotunda Hospital, Dublin, Ireland. It was published online on May 22, 2025, in the European Journal of Pediatrics . LIMITATIONS: This study was limited by the dataset being unbalanced, with most neonates born to mothers with GD. Neonates of mothers without diabetes requiring NICU admission were not included. Factors such as maternal smoking, raised BMI, or preeclampsia possibly confounded the NICU admission risk. DISCLOSURES: Open access funding was provided by the IReL Consortium. The authors reported having no relevant conflicts of interest.
